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harmacogenomics
nd the Failing Heart
re We Waiting for Godot?*
ouglas L. Mann, MD, FACC,†
ennis M. McNamara, MD, FACC‡
ouston, Texas; and Pittsburgh, Pennsylvania
n Samuel Beckett’s play, Waiting for Godot, the characters
ait by a country roadside for a person named Godot, who
ever arrives (1). Godot’s conspicuous absence throughout
he play has fostered a variety of different religious, philo-
ophical, and psychoanalytical interpretations, and has led
o the use of the phrase “waiting for Godot” as an expression
or waiting for someone or something that will never arrive.
ver the past several years, a series of intriguing observa-
ions has arisen with regard to the role genetic variations
polymorphisms) in signaling pathways that contribute to
isease progression in the failing heart (2,3). These obser-
ations have given rise to the hope that information regard-
ng genetic polymorphisms might be harnessed to develop
ersonalized therapeutic strategies for patients with heart
ailure. However, this type of genetic information has not
een clinically useful thus far, insofar as many of the genetic
ssociations that have been reported have not been inde-
endently replicated.
See page 644
In this issue of the Journal, Sehnert et al. (4) report on the
ack of association between adrenergic receptor genotypes
nd all-cause mortality and transplant-free survival in heart
ailure patients who were treated with 2 beta-blockers that
ave been shown to confer a survival benefit (metoprolol
uccinate and carvedilol) (5). The investigators identified
37 patients enrolled in 2 separate cardiovascular gen-
tic registries who were discharged on beta-blockers,
ngiotensin-converting enzyme inhibitor or angiotensin re-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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edical Center, Pittsburgh, Pennsylvania. Supported by research funds from thei
ational Institutes of Health (UO1 HL084890, RO1 HL73017, RO1 HL58081,
O1 HL61543).eptor blocker, and a diuretic. Heart failure was defined by
he presence of a left ventricular ejection fraction (LVEF)
40% and/or a history of heart failure at the time of heart
atheterization. The investigators genotyped 5 polymor-
hisms in 3 genes (Table 1): the beta-1 adrenergic receptor
ADRB1) (Ser49Gly, Arg389Gly), the beta2-adrenergic
eceptor (ADRB2) (Gly16Arg, Gln27Glu), and a loss of
unction deletion mutation (2C Del322_325) in the
lpha2C-adrenergic receptor (ADRA2C). They analyzed the
ssociation of single-nucleotide polymorphisms (SNPs) and
aplotypes for ADRB1, ADRB2, and ADRAC with respect
o the clinical end points of all-cause death and/or
ransplant-free survival. Importantly, there was no signifi-
ant effect of SNPs or haplotypes of ADRB1, ADRB2, and
DRA2C genes on all-cause death or transplant-free sur-
ival in either the metoprolol-treated or carvedilol-treated
eart failure patients. To address the potential significance
f this study vis-a-vis the quest to develop personalized
enomic strategies for treating patients with heart failure, it
s useful to discuss what is known about genetic variations in
drenergic signaling and the failing heart.
enetic variations in the adrenergic signaling pathway.
lthough activation of the adrenergic activation serves to
nhance and/or stabilize myocardial performance in the
ailing heart, excessive myocardial adrenergic signaling is
rankly cardiomyopathic, and is believed to contribute to
isease progression in heart failure (5). Indeed, the benefi-
ial effects of beta-blocking agents seem to be caused by
heir ability to prevent the deleterious effects of cat-
cholamines on the heart and the circulation. However,
linical studies have also shown that beta-blocker therapy
ften produces variable responses among patients with heart
ailure (6). Given the existence of genetic polymorphisms in
he ADRB1, ADRB2, and ADRA2C genes (Table 1), it has
een suggested that genetic variations in individuals may
ccount for, at least in part, the variable responses to
eta-blockers in heart failure patients (6). For example,
eta-blockers would be expected to be more beneficial in
atients carrying genotypes associated with higher, rather
han lower, activity of the ARBR1 gene. As shown in Table
, a common SNP in the ADBR1 gene, Arg389Arg, leads to
nhanced ADBR1 signaling. The ADRA2C deletion muta-
ion leads to a reduction in inhibition of norepinephrine
elease from the pre-synaptic nerve terminals by 2c-
eceptors, and therefore results in increased adrenergic
rive. In contrast to ADBR1 polymorphisms, the investiga-
ion of ADBR2 polymorphisms seems less consistent in
eart failure, and there is less evidence of their influence on
he effectiveness of beta-blockade (7).
Although a number of studies have examined the role of
harmacogenetic interactions of beta-blockers with respect
o changes in LVEF and cardiac remodeling (reviewed in
hin and Johnson [6] and Muthumala et al. [7]), there are
nly a few studies that have examined pharmacogenetic
nteractions of beta-blockers in relation to clinical end
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substudy of the MERIT HF (Metoprolol CR/XL Ran-
omized Intervention Trial in Chronic Heart Failure), in
hich 307 patients on metoprolol and 293 patients on
lacebo were genotyped for polymorphisms in the ADBR1
ene and followed up for 12 months, there was no associ-
tion between the ADRB1 genotype and all-cause death
nd/or hospitalization (8). Although this study suggests that
here is a lack of interaction between genotype and beta-
lockers for clinically meaningful outcomes, it bears empha-
is that this substudy compared outcomes between ADBR1
enotypes irrespective of their treatment assignment, which
akes it difficult to evaluate the genetic association of
linical outcomes relative to beta-blocker therapy. In con-
rast, the BEST (Beta-blocker Evaluation of Survival Trial)
howed a significant reduction in mortality and heart failure
ospitalization in bucindolol-treated versus placebo-treated
eart failure patients who were homozygous for the
rg389Arg ADBR1 allele (9). Notwithstanding the impor-
ant pharmacological differences between bucindolol, used
n the BEST trial, and metoprolol succinate and carvedilol,
sed in the registry study by Sehnert et al. (4), there are
everal significant differences between prospective clinical
rials and cohort registries that are important when inter-
reting clinical outcomes in pharmacogenomic studies. The
ost obvious difference is that in prospective clinical trials
he patients are randomized to control and treatment
roups, are carefully clinically phenotyped at the time of
ntry into the study, and are then closely followed up
ongitudinally. In contrast, in registry studies the patients
re not randomized and many details regarding clinical
henotyping and background therapies are often not avail-
ble. These types of differences can lead to potential bias
nd/or confound the results of the study. For example, if a
iven SNP in the adrenergic pathway leads to hyperactiva-
ion of a beta-receptor (e.g., 389Arg389), and this hyper-
ffect of Gene Polymorphisms on the Pharmacological Treatment o
Table 1 Effect of Gene Polymorphisms on the Pharmacological
Gene Polymorphism F
ADBR1 Arg to Gly switch at codon 389
(Arg389Gly)
Arg389 allele has
activity in respo
variant
ADBR1 Ser to Gly switch at codon 49
(Ser49Gly)
Ser49 allele has d
regulation and
ADBR2 Gly to Arg switch at codon 16
(Gly16Arg)
Gly16 allele has g
regulation
ADBR2 Gln to Glu switch at codon 27 Glu27 allele is res
ADRA2C Deletion mutation of aa 322-325
(2CDel322-325)
Loss of function m
NE uptake
rg arginine; BEST Beta-blocker Evaluation of Survival Trial; Gln glutamine; Glu glutamic
serine.unction confers an adverse outcome that is eliminated by teta-blockers, then it is not possible to determine any effect
f beta-blockade if all of the patients were receiving beta-
lockers. Thus, by virtue of using modern clinical registries
n which all of the heart failure patients were receiving
eta-blockers, Sehnert et al. (4) were less likely to observe
mportant pharmacogenetic interactions between beta-
lockers and the ADBR genotype. Moreover, there was no
nformation regarding the dose of neurohormonal antago-
ists that were used during the study, and/or whether these
gents were up-titrated to doses that have been shown to
roduce clinical benefits in heart failure patients. Similarly,
lthough it was possible to confirm that at least half of the
atients were taking beta-blockers at 60 days after being
egistered in the study, it was not clear from the database
hat patients were compliant with their beta-blockers at the
ime of death and/or cardiac transplantation. Given that the
alutary effects of beta-blockers are dose-dependent and
ime-dependent, it becomes difficult to draw firm conclu-
ions regarding potential pharmacogenomic interactions
nd heart failure outcomes. Thus, the study by Sehnert et al.
4), although thoughtfully analyzed and presented, cannot
e viewed as definitive with respect to the lack of association
etween ADBR genotypes and survival in heart failure
atients treated with either carvedilol or metoprolol. That
aid, it may well be that analyses of SNPs will never
ompletely predict drug responsiveness in a disease as
omplex as heart failure, in which case the heuristic value of
he study by Sehnert et al. (4) is that it illustrates the
mportance of designing, funding, and conducting prospec-
ive genome-wide association studies that will better define
he role of pharmacogenomics in patients with heart fail-
re . . . lest we remain waiting for Godot.
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